Emerging Drug Discovery Alliance Models By Dr Swati Prasad, Mary Louise Bell & Dr Charles McOsker The current environment for early-stage drug discovery and development is fluid and the probability of success continues to be challenging. Advancing an idea from an academic or basic research setting into a therapeutic product… Read More
Oral Peptide Therapeutics - A Holy Grail or Quixotic Quest? By Dr Paul Shields Technologies have been honed to overcome many of the challenges of administering peptide therapeutics orally, but obstacles remain before drug developers can fully realise the vast potential. Proteins and peptides are the building blocks of life… Read More
Phenotypic Screening - Advancing the science from discovery to regulatory science By Dr Ellen L. Berg Phenotypic screening is transforming drug discovery as advances are made in development of human-based physiologically-relevant in vitro systems. Integration of phenotypic drug discovery approaches with target-based screening can improve success rates as assays can… Read More
Collaborative Robots Are Redefining Lab Automation By Peter Harris The use of robots to automate high-volume repetitive tasks has been common practice going back to the early 1970s, when the German company KUKA developed and deployed the first electromechanical industrial robot. Subsequently, the world began replacing human effort in high-volume… Read More
New Approaches to Sample Identification Tracking and Technologies for Maintaining Stored Sample Quality By Dr John Comley Safeguarding the quality of stored samples (both compounds and biospecimens) must be the driving ethos in compound management stores and biorepositories. Yet there are few innovations in available sample storage technologies that can… Read More
Raising The Bar On The Biologics Potential Dr Michael Mouradian In the quest for safe, efficacious and profitable therapies, pharma research is changing. There is continued pressure to fill the drug pipeline and, at the same time, globalisation of personalised medicines is complex, expensive and requires a significant time commitment. Read More
Advancing the Drug Discovery Pipeline with Early Stage In Vitro ADME and Toxicity Testing By Dr Maureen Bunger With increasing pressures on pharmaceutical companies to develop new, effective therapeutics across the board, and keep the costs of development down, the drug discovery industry needs to ensure that its standard processes… Read More
3D Cell Culture - A Rapidly Emerging Technique for Drug Discovery By Hannah Gitschier, Dr Ye Fang and Dr Richard M. Eglen The past decades have witnessed significant efforts toward the development of three-dimensional (3D) cell cultures. Today, 3D cell cultures are emerging not only as a new tool in… Read More
Spheroids Rapidly Becoming a Preferred 3D Cell Culture Format By Dr John Comley There are many advantages associated with culturing cells in three-dimensional (3D) versus conventional two-dimensional (2D) tissue culture. Scaffold-free 3D cell culture systems that generate spheroids (and other similar multicellular aggregations) have proved useful as they offer an… Read More
A Strategic Vision For 21st Century Drug Discovery By Dr Wayne Bowen, Dr Giles Sanders, Dr Andreas Werdich, Dr Brian Warrington and Dr Elizabeth Farrant Delivering genuine therapeutic innovation is more challenging and complex than ever. Despite major scientific breakthroughs and technological advances leading to a greater understanding of the… Read More
Automated Liquid Handler Vendor vs Third Party Plastic Company by Dr John Comley Competing for the disposable pipette tip business. Users of automated liquid handlers today invariably have a choice – obtain disposable pipette tips from the original instrument vendor or purchase a 'compatible' product from a third party plastics… Read More
Translational Chemical Biology: Gap assessment for advancing drug discovery, development and precision medicine By Dr Mukund Chorghade, Dr Michael Liebman, Dr Gerald Lushington, Dr Stephen Naylor and Dr Rathnam Chaguturu As yesterday’s lead molecule enters today’s clinical trial, the standard operating script seems to call for product developers and clinicians… Read More
3D Cellular Imaging - Advances and Considerations for High-Content Screening By O. Joseph Trask, Dr Daniel V. LaBarbera and Dr Kevin Quick Commercially available high-content imaging (HCI) systems, introduced in the 1990s, have provided the scientific community with a platform that offers a unique set of tools ideal for advancing… Read More
I Robot. I, The Future - Robotics Within and Beyond The Lab Richard Holland The Pistoia Alliance (whose membership includes most of the world’s major pharmaceutical companies, technology vendors and publishers active in the life science R&D sector), is keenly interested in discovering the ways in which innovation through pre-competitive… Read More
CRISPR Cas9: Transforming Gene Editing in Drug Discovery Labs By Dr John Comley It is evident from a recent market survey on gene editing in drug discovery that CRISPR/Cas9 is now recognised as the superlative method when attempting a gene knockout or when introducing defined mutations, insertions or modifications to… Read More
Breath Based Biomarker Detection & Breath Biopsy - Informing drug development and future treatment regimes By Billy Boyle and Dr Mike Murphy The recent approval of the first liquid biopsy test for the diagnosis of non-small cell lung cancer (NSCLC) demonstrates how biomarker-based detection tools are becoming important components of… Read More